INSMED INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.8 USD | -0.48% |
|
+1.97% | -19.97% |
Presenter SpeechLeon Wang (Analysts)All right. So wrapping up day 2 of the Barclays Global Hea...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).
Calendar
2024-05-08
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
24.8
USD
Average target price
44.12
USD
Spread / Average Target
+77.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.97% | 3.68B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- INSM Stock
- News Insmed Incorporated
- Transcript : Insmed Incorporated Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 04
